

# **EXHIBIT A**

## KIRKLAND & ELLIS LLP

AND AFFILIATED PARTNERSHIPS

655 Fifteenth Street, N.W.  
Washington, D.C. 20005

202 879-5000

www.kirkland.com

Corey J. Manley  
To Call Writer Directly:  
202 879-5940  
cmanley@kirkland.com

Facsimile:  
202 879-5200

December 13, 2006

### By Facsimile

Cristina Ashworth, Esq.  
Wilmer Cutler Pickering Hale and Dorr LLP  
1875 Pennsylvania, Avenue, N.W.  
Washington, D.C. 20006

Re: *Smith Kline & French Laboratories, LTD and SmithKline Beecham Corp.,  
d/b/a GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc.*, Civil Action  
No. 05-197 (GMS) (D.Del.)

Dear Tina:

We received GSK's revised exhibit list today. In light of today's joint stipulation, enclosed please find Teva's updated exhibit list, a corresponding newly marked exhibit, and Teva's revised proposed joint exhibit list.

With respect to Teva's updated exhibit list, DTX 390, a document produced as part of your expert production for Dr. Jenner, has been added, and DTX 44-46, 53-55, 57-61, 65, 66, 171, 177, 178, 184, 354, 360, and 369 have been withdrawn. A marked, hard copy of DTX 390 is enclosed.


With respect to Teva's revised proposed joint exhibit list, the following exhibits have been added that have not previously appeared on either party's proposed joint exhibit lists: DTX 28, DTX 39, DTX 71, DTX 96, DTX 106-108, DTX 112, DTX 113, DTX 132-134, DTX 136-138, DTX 140-142, DTX 192, DTX 204, DTX 243, DTX 243.1, DTX 243.2, DTX 244, DTX 245, DTX 248, DTX 250-253, DTX 255-258, DTX 260, DTX 262, DTX 267, DTX 269, DTX 277, DTX 290, DTX 297, DTX 303, DTX 316, DTX 321, DTX 341, DTX 343-353, DTX 371-376, DTX 383-390, PTX 413, PTX 431.

We look forward to working with you to resolve outstanding exhibit issues, including finalizing the parties' joint exhibit list shortly.

Cristina Ashworth  
December 13, 2006  
Page 2

KIRKLAND & ELLIS LLP

Sincerely,



Corey J. Manley

Enclosures

cc: Michael Gordon  
Mark Rienzi

**DRAFT—EXHIBIT 9 TO PRETRIAL ORDER****UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

AO 187

<b>SMITH KLINE &amp; FRENCH LABORATORIES, LTD. AND SMITHKLINE BEECHAM CORP., D/B/A GLAXOSMITHKLINE,</b>  <b>Plaintiffs,</b>  <b>v.</b>  <b>TEVA PHARMACEUTICALS USA, INC.,</b>  <b>Defendant.</b>		<b>EXHIBIT LIST</b>  <b>Case No. 05-197 (GMS)</b>
<b>PRESIDING JUDGE:</b> Honorable Gregory M. Sleet	<b>PLAINTIFFS' ATTORNEYS:</b>	<b>DEFENDANT'S ATTORNEYS:</b> Daniel F. Attridge, P.C. Edward C. Donovan
<b>TRIAL DATES:</b> 12/18/2006 - 12/22/2006	<b>COURT REPORTER:</b>	<b>COURTROOM DEPUTY:</b>

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 1				
	DTX 2				
	DTX 3				
	DTX 4				
	DTX 5				
	DTX 6				
	DTX 7				
	DTX 8				
	DTX 9				
	DTX 10				
	DTX 11				
	DTX 12				

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 13				
	DTX 14				
	DTX 15				
	DTX 16				
	DTX 17				
	DTX 18				
	DTX 19				TEV-RQEXP000529-586, Prosecution History for '860 Patent
	DTX 20				TEV-RQEXP000587-638, Prosecution History for '808 Patent
	DTX 21				GSK-REQ024523-610, Hieble, J.P. and R.M. DeMarinis memo to Dr. B. Berkowitz, Dr. S. Hecht re <i>Recommendation (sic) of SK&amp;F 85738, 89124 and 101468 for Development Project Status</i> , May 25, 1984
	DTX 22				DX-22, Eden, R., Curriculum Vitae
	DTX 23				DX-23, SK&F Project Meeting Minutes March 13, 1986
	DTX 24				DX-24, Wright, A., Laboratory Notebook, July 2, 1986
	DTX 25				DX-25, SK&F Project Meeting Minutes February 27, 1987
	DTX 26				DX-26, R. Eden et al., <i>Preclinical Pharmacology of Ropinirole (SK&amp;F 101468-A) a Novel Dopamine D2 Agonist</i> , 1991
	DTX 27				DX-27, GSK Retainer Agreement, August 6, 2005
	DTX 28				DX-28, Draft Project Plan, August 1987
	DTX 29				DX-29, J.P. Hieble and R. DeMarinis memo to Berkowitz, B. and S. Hecht re <i>Recommendation for Development Project Status</i> , May 25, 1984
	DTX 30				DX-30, G. Gallagher et al: 4-[2-(Di-n-propylamine)ethyl]-2(3H) indolone: <i>A Prejunctional Dopamine Receptor Agonist</i> , J. Med. Chem. 28: 1533-1536 1985

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 31				DX-31, B. Costall et al, <i>Quantitative Assessment of MPTP-Induced Parkinsonism in the Common Marmoset (Callithrix jacchus)</i> , School of Pharmacy, University of Bradford
	DTX 32				GSK-REQ024778-780, Cannon et al., <i>Proposed Dopaminergic Pharmacophore of Lergotriple, Pergolide and Related Ergot Alkaloid Derivatives</i> , J. Med. Chem.-Communications to the Editor, 24:238-240 1981
	DTX 33				DX-33, Costall, B., Curriculum Vitae
	DTX 34				DX-34, <i>Symposium: Dopamine Agonists in Parkinson's Disease - A Competitive Product</i> , November 21, 1989
	DTX 35				DX-35, B. Costall and R.J. Naylor: <i>SK&amp;F 101468-A: a centrally acting dopamine agonist having antiparkinson, antidepressant and anxiolytic activity</i> , July 9, 1987
	DTX 36				DX-36, Costall, B. and R.J. Naylor, <i>Action of SK&amp;F 101468-A in mice with unilateral 6-OHDA lesions of the substantia nigra</i> , September 1987
	DTX 37				DX-37, Costall, B. and R.J. Naylor, <i>Action of SK&amp;F 101468-A in a Model of Parkinson's Disease induced by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the common marmoset</i> , September 1987
	DTX 38				DX-38, Costall, B. et al., <i>The Effects of chronic administration of SK&amp;F 101468-A in the MPTP-treated common marmoset (Callithrix jacchus)</i> , May 1989
	DTX 39				DX-39, Preclinical Profile of SK&F 101468-A (Ropinirole)
	DTX 40				GSK-JEN000106-112, Cannon, J., <i>The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids?</i> , The Proceedings of The Iowa Academy of Science 93(4): 169-174, 1986
	DTX 41				DX-41, Teva's Notice of 30(b)(6) Deposition April 5, 2006
	DTX 42				DX-42, Gallagher, G., U.S. Patent 4,452,808, June 5, 1984
	DTX 43				DX-43, Profile of Ropinirole and SK&F #89124

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 47				DX-47, Huffman et al., U.S. Patent 4,314,944, February 9, 1982
	DTX 48				DX-48, Owen et al., U.S. Patent 4,824,860, April 25, 1989
	DTX 49				DX-49, Hieble, J.P. memo to R. Eden re <i>Potential Back-Up Compounds for SK&amp;F 101468 as Anti-Parkinson's Drugs</i>
	DTX 50				DX-50, Hieble, J.P. memo to R. Eden re <i>Potential Back-Up Compounds for SK&amp;F 101468 as Anti-Parkinson's Drugs</i>
	DTX 51				DX-51, R&D Program Project Reviews re SK&F 85174 Project, February 1, 1983
	DTX 52				DX-52, J.P. Hieble et al, <i>Activity of SK&amp;F 89124-A in Several In Vitro Reception Assays</i> , May 1987
	DTX 56				DX-56, R. DeMarinis et al, <i>Syntheses and In Vitro Evaluation of 4-(2-aminoethyl)-2-3(H)-Indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists</i> , 1986
	DTX 62				DX-62, J. Cannon et al: <i>Proposed Dopaminergic Pharmacophore of Lergotile. Pergolide, and Related Ergot Alkaloid Derivatives</i> J. Med. Chem. 24:238-240 (1981)
	DTX 63				DX-63, <i>A hypothetical indole with the hydroxy at position 7 removed.</i> Drawing.
	DTX 64				DX-64, Huffinan, W. et al., <i>Communications to the Editor re 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a Novel Class of Potent Presynaptic Dopamine Receptor Agonists</i> , J. Med. Chem., July 1983
	DTX 67				GSK-JEN000061-66, Cannon, J., <i>Preparation and Biological Actions of Some Symmetrically N,N-Disubstituted Dopamines</i> , J. Med. Chem., 1978, Vol. 21, No. 3
	DTX 68				DX-68, SK&F Project Meeting Minutes December 4, 1985
	DTX 69				DX-69, SK&F Project Meeting Minutes January 9, 1986
	DTX 70				DX-70, SK&F Project Meeting Minutes December 9, 1985

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 71				DX-71, Department of Drug Metabolism and Pharmacokinetics: <i>Preliminary Investigation into the C.N.S. Penetration of SK&amp;F 101468 and Related Material in the Conscious Rat</i> , March 1986
	DTX 72				DX-72, SK&F Project Meeting Minutes, February 10, 1986
	DTX 73				DX-73, SK&F Project Meeting Minutes, April 18, 1986
	DTX 74				DX-74, SK&F Project Meeting Minutes, May 20, 1986
	DTX 75				DX-75, SK&F Project Meeting Minutes, September 3, 1986
	DTX 76				DX-76, SK&F Project Meeting Minutes, October 30, 1986
	DTX 77				DX-77, SK&F Project Meeting Minutes, December 11, 1986
	DTX 78				DX-78, SK&F Project Meeting Minutes, February 18, 1987
	DTX 79				DX-79, SK&F Project Meeting Minutes, February 27, 1987
	DTX 80				DX-80, Welwyn Project Operating Committee Meeting Minutes, May 20, 1987
	DTX 81				DX-81, Minutes of the Medical Review Board Meeting, June 5, 1987
	DTX 82				DX-82, Welwyn Project Operating Committee Meeting Minutes, June 17, 1987
	DTX 83				DX-83, Ormsbee, H.S. memo re <i>Project Management Committee Meeting Minutes for 06/04/1987</i> , June 19, 1987
	DTX 84				DX-84, SK&F Project Meeting Minutes, July 1, 1987
	DTX 85				DX-85, Welwyn Project Committee Meeting Minutes, October 7, 1987
	DTX 86				DX-86, SK&F Project Review Panel memo to SK&F 101468 Project Team re <i>Critique of SK&amp;F 101468</i> , October 12, 1987
	DTX 87				DX-87, SK&F Project Meeting Minutes November 11, 1987



Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 88				DX-88, Ormsbee, H.S., memo to Project Management Team re <i>SK&amp;F Project Management Committee Meeting Minutes for 11/04/1987</i> , November 23, 1987
	DTX 89				DX-89, SK&F Project Meeting Minutes, March 3, 1988
	DTX 90				DX-90, SK&F Project Meeting Minutes May 18, 1988
	DTX 91				DX-91, Symposium Itinerary: <i>Dopamine Agonists in Parkinson's Disease - A Competitive Product</i> , November 21, 1989
	DTX 92				DX-92, <i>SK&amp;F 101468 Worldwide Development Plan and Review Document</i> , September 1987
	DTX 93				DX-93, Costall, B. et al., <i>Pharmacological Evaluation of SK&amp;F 101468-A in MPTP Treated Marmosets</i> , 1990
	DTX 94				DX-94, Hieble, J.P. et al., <i>Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on the Intact Animal</i>
	DTX 95				GSK-REQ064624-64683, Requip PD: Strat Plan 2005 Presentation
	DTX 96				DX-96, Wixon, H. email to D. Owen re GSK Retention Confirmation
	DTX 97				DX-97, Owen, D., Declaration and Power of Attorney, May 19, 1988
	DTX 98				DX-98, SK&F Project Meeting Minutes May 29, 1986
	DTX 99				DX-99, SK&F Project Meeting Minutes September 28, 1988
	DTX 100				DX-100, SK&F Project Meeting Minutes October 30, 1986
	DTX 101				DX-101, SK&F Project Meeting Minutes July 16, 1986
	DTX 102				DX-102, SK&F Project Meeting Minutes September 3, 1986
	DTX 103				DX-103, Sulpizio, A. et al., <i>Aminoethylindolones: D<sub>2</sub> Without Apparent CNS Effects</i>
	DTX 104				DX-104, SK&F Project Meeting Minutes July 1, 1987
	DTX 105				DX-105, SK&F Project Meeting Minutes May 18, 1988

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 106				DX-106, GSK Supplemental Responses to Teva's 1 <sup>st</sup> Set of Interrogatories, April 10, 2006
	DTX 107				DX-107, Strategic Brand Plan: (01) Brand Summary
	DTX 108				DX-108, ReQuip 2001 Situational Analysis, May 14, 2001
	DTX 109				DX-109, Ropinirole Q & A
	DTX 110				DX-110, ReQuip Situation Analysis Data Pack, 2006
	DTX 111				DX-111, ReQuip IR and ReQuip 24-Hour 2006 Strategic Plan
	DTX 112				DX-112, Strategic Brand Plan Situation Analysis, June 7, 2001
	DTX 113				DX-113, ReQuip Differentiation Strategy Approach Topline Report
	DTX 114				DX-114, Crosbee Group Inc., <i>Initial Observations and Insights - PD Differentiation Strategy Focus Groups</i> , September 30, 2002
	DTX 115				DX-115, Parkinson's Disease Market Dynamics Tracking Study, <i>Table 22-1: ReQuip Used in Combination with Other First Line Therapies</i> , August 2001
	DTX 116				DX-116, Connections Bonding Report re REQUIP Physicians Messaging Options For Further Discussion, February 20, 2004
	DTX 117				DX-117, ReQuip PCP Viability Study March 20, 2002
	DTX 118				DX-118, <i>Return on Investment Analysis: Promotion of ReQuip to Primary Care Physicians</i> , Draft Review, March 21, 2002
	DTX 119				DX-119, ReQuip Neuro Research, April 8, 2002
	DTX 120				DX-120, ReQuip 2001 Tactical Plan Revised, December 21, 2000
	DTX 121				DX-121, ReQuip 2001 Tactical Plan
	DTX 122				DX-122, RLS and PD Competitors Chart, May 2005
	DTX 123				DX-123, Strategic Pricing Current Price Position REQUIP
	DTX 124				DX-124, Carpenter, V., GSK Competitor Review

<b>Plf. No.</b>	<b>Def. No.</b>	<b>Date Offered</b>	<b>Marked</b>	<b>Admitted</b>	<b>Description of Exhibits and Witnesses</b>
	DTX 125				DX-125, ReQuip Brand P&L Chart, 1997-2005
	DTX 126				DX-126, ReQuip Revenue Consensus Forecast, 2001-2008
	DTX 127				DX-127, ReQuip 2004 Situation Analysis Summary .
	DTX 128				DX-128, ReQuip Market TRxs Chart
	DTX 129				DX-129, Parkinson's Product Use Qualitative Research Summary Report January 2002
	DTX 130				DX-130, Giddings, P.J., British Patent Application - 8712073
	DTX 131				DX-131, Medicament - Abstract of the Disclosure
	DTX 132				DX-132, Revised Privilege Log of GSK April 18, 2006
	DTX 133				DX-133, Giddings, P.J., letter to European Patent Office, November 25, 1991
	DTX 134				DX-134, European Patent Office letter to P.J. Giddings, July 26, 1991
	DTX 135				DX-135, SK&F Project Meeting Minutes August 8, 1987
	DTX 136				DX-136, Second Privilege Log of GSK May 2, 2006
	DTX 137				DX-137, Third Privilege Log of GSK May 24, 2006
	DTX 138				DX-138, Fourth Privilege Log of GSK May 31, 2006
	DTX 139				GSK-REQ064062-64063, The Strategic Brand Plan: Situation Analysis
	DTX 140				Plaintiff GSK's Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, October 3, 2005
	DTX 141				Plaintiff GSK's Supplemental Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, April 10, 2006
	DTX 142				Plaintiff GSK's 2 <sup>nd</sup> Supplemental Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, June 29, 2006
	DTX 143				Plaintiff GSK's Responses to Defendant's 2 <sup>nd</sup> Set of Interrogatories, April 14, 2006
	DTX 144				Plaintiff GSK's Supplemental Responses to Defendant's 2 <sup>nd</sup> Set of Interrogatories, June 29, 2006

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 145				Plaintiff GSK's Responses to Defendant's 1 <sup>st</sup> Set of Requests for Production of Documents and Things, October 3, 2005
	DTX 146				Plaintiff GSK's Supplemental Responses to Defendant's 1 <sup>st</sup> Set of Requests for Production of Documents and Things, June 29, 2006
	DTX 147				Plaintiff GSK's Responses to Defendant's 2 <sup>nd</sup> Set of Requests for Production of Documents and Things, April 27, 2006
	DTX 148				Plaintiff GSK's Supplemental Responses to Defendant's 2 <sup>nd</sup> Set of Requests for Production of Documents and Things, June 29, 2006
	DTX 149				GSK-REQ 004723-734, Gallagher, G. memo to J.W. Wilson and S. Ross re <i>Cardiovascular Research Chemistry Report Antianginal/Antihypertension Project November 1, 1981 to April 30, 1982</i>
	DTX 150				GSK-REQ005139-142, Costall, B., Eden R.J., Harvey, C.A., Kelly, M.E. and Owen, D.A.A., <i>SK&amp;F 101468-A, A Possible Drug for Treatment of Parkinson's Disease</i> , Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, 1990, Vol. 2, ed. by T. Nagatsu et al., Plenum Press, New York.
	DTX 151				GSK-REQ006755-762, Eden, R.J., Wallduck, M.S., Patel, B. and Owen, D.A.A., <i>Autonomic and Haemodynamic responses to SK&amp;F 101468 (ropinirole), a DA<sub>2</sub> agonist, in anaesthetised cats</i> , European J. of Pharmacology, 1990, Vol. 175: 333-340.
	DTX 152				GSK-REQ011542-594, Gallagher, G., Prosecution History for U.S. Patent No. 4,452,808, <i>4-Aminoalkyl-2(3H)-Indolones</i>
	DTX 153				GSK-REQ011595-653, Owen, D., Prosecution History for U.S. Patent No. 4,482,860, <i>Treatment of Parkinson's Disease</i>
	DTX 154				TEV-RQEXP000001-004, Acheson, R.M., <i>An Introduction to the Chemistry of Heterocyclic Compounds</i> , John Wiley & Sons, 1976.
	DTX 155				TEV-RQEXP000005-014, Bhatnagar, R.K., Arneric, S.P., Cannon, J.G., Flynn, J. and Long, J.P., <i>Structure Activity Relationships of Presynaptic Dopamine Receptor Agonists</i> , Pharmacol. Biochem. & Behavior, 1982, Vol. 17, No. 1:11-19.

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 156				TEV-RQEXP000015-018, Camerman, N. and Camerman, A., <i>On the Stereochemistry of Dopaminergic Ergoline Derivatives</i> , Molecular Pharmacology, 1981, Vol. 19:517-519.
	DTX 157				TEV-RQEXP000019-028, Canas-Rodriguez, A. and Leeming, P.R., <i>N-Phenyl-2-indolinones and N-Phenylindolines. A New Class of Antidepressant Agents</i> , J. Med. Chem., 1972, Vol. 15, No. 7: 762-770.
	DTX 158				TEV-RQEXP000029-040, Cannon, J.G., <i>Dopamine Congeners Derived from the Benzo(f)-quinoline Ring</i> , Adv. in Biosciences, 1979, 20: 87-94.
	DTX 159				TEV-RQEXP000041-046, Cannon, J.G. and Demopoulos, B.J., <i>Synthesis of N-Alkyl Derivatives of 4-(2'-Aminoethyl)indole</i> , J. Heterocyclic Chem., 1982, Vol. 19, 1195-99
	DTX 160				TEV-RQEXP000047-052, Cannon, J.G., Hsu, F., Long, J.P., Flynn, J.R., Costall, B., and Naylor, R.J., <i>Preparation and Biological Actions of Some Symmetrically N, N-Disubstituted Dopamines</i> , J. Med. Chem., 1978, Vol. 21, No. 3: 248-253.
	DTX 161				TEV-RQEXP000053-056, Cannon, J.G., Lee, T., Ilhan, M., Koons, J. and Long, J.P., <i>6-Hydroxy-4-[2-(di-n-propylamino)ethyl]indole: Synthesis and Dopaminergic Actions</i> , J. of Medicinal Chemistry, 1984, Vol. 27: 386.
	DTX 162				TEV-RQEXP000057-058, Cannon, J.G., Long, J.P. and Demopoulos, B.J., <i>Indole-Derived Fragments of Ergot Alkaloids as Dopamine Congeners</i> , 8 <sup>th</sup> International Congress of Pharmacology, Satellite Symposium.
	DTX 163				TEV-RQEXP000059-072, Costall, B. and Naylor, R.J., <i>Actions of Dopaminergic Agonists on Motor Function</i> , Advances in Neurology, 1975, Vol. 9, ed. By D.B. Calne, T.N. Chase and A. Barbeau, 293.
	DTX 164				TEV-RQEXP000073-080, Geissler, H., <i>3-{2-(Dipropylamino)ethyl}phenol : a new and selective dopaminergic agonist</i> , Arch. Pharm. (Weinheim), 1977, Vol. 310:749-756.
	DTX 165				TEV-RQEXP000081-106, Goldberg, L.I., Volkman, P.H. and Kohli, J.D., <i>A Comparison of the Vascular Dopamine Receptor with Other Dopamine Receptors</i> , Ann. Rev. Pharmacol. Toxicol., 1978, Vol 18: 57-79.



Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 166				TEV-RQEXP000107-110, Goodman, L.S. and Gilman, A., editors, <i>The Pharmacological Basis of Therapeutics</i> , McMillan Publ. Co., Inc., New York, 1975.
	DTX 167				TEV-RQEXP000111-114, Joule, J.A. and Smith, G.F., <i>Heterocyclic Chemistry</i> , 1972, p. 278.
	DTX 168				TEV-RQEXP000115-186, Kelly, E.A., <i>Synthesis of Ergoline analogs for Biological Evaluation</i> , A Thesis Submitted to the Faculty of Purdue University, December 1978.
	DTX 169				TEV-RQEXP000187-190, Korolkovas, A., <i>Essentials of Molecular Pharmacology</i> , John Wiley & Sons, Inc., New York, 1970.
	DTX 170				TEV-RQEXP000191-204, Long, J.P., Gebhart, G.F., Flynn, J.R. and Cannon, J.G., <i>Vascular and Cardiac Actions of N-di-Alkyl Dopamine Analogs</i> , Arch. Int. Pharmacodyn., 1980, Vol 245: 104-117.
	DTX 172				TEV-RQEXP000217-220, Steinsland, O. and Hieble, J.P., <i>Dopaminergic Inhibition of Andrenergic Neurotransmission as a Model for Studies on Dopamine Receptor Mechanisms</i> , Science, 1978, Vol. 199:443-445.
	DTX 173				TEV-RQEXP000221-226, Stutz, P.L., Stadler, P., Vigouret, J.M., and Jaton, A. <i>Derivative von (5R, 8S, 10R)-8-Amino-6-methylethylergolin als zentral wirksame dopaminerge Stimulation</i> , Eur. J. Med. Chem. - Chim. Ther., 1982-17, No. 6, pp. 537-541.
	DTX 174				TEV-RQEXP000227-228, Stutz, P.L., Stadler, P., Vigouret, J.M., and Jaton, A. <i>Ergot alkaloids. New ergolines as selective dopaminergic stimulants</i> , J. Med. Chem. 1978, 21 (8): 754-7.
	DTX 175				TEV-RQEXP000229-236, Summers, C. Dijkstra, D., deVries, J. and Horn, A., <i>Neurochemical and Behaviour Profiles of Five Dopamine Analogues</i> , Naunyn-Schmeideberg's Arch. Pharmacol., 1981, Vol. 316:304-310.
	DTX 176				TEV-RQEXP000237-238, Taylor, A.A., Fennell, W.H. and Mitchell, J.R., <i>Propylbutyldopamine Increases Renal Blood Flow and Decreases Blood Pressure in Man by Activation of DA<sub>1</sub> and DA<sub>2</sub> Dopamine Receptors</i> , Clinical Research, 1982, Vol 30, No 2.

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 179				TEV-RQEXP000249-254, Cannon, J.G., <i>The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids?</i> Proc. Iowa Acad. Sci., 1986, Vol. 93, No. 4: 169-174.
	DTX 180				GSK-REQ000993-1074, SB Report No. PW005BA, SmithKline Beecham Pharmaceuticals, <i>SK&amp;F 101468-A: a centrally acting dopamine agonist having antiparkinson, antidepressant and anxiolytic activity</i> , September 1986
	DTX 181				GSK-REQ001309-25, SB Report No. PP011BA, SmithKline Beecham Pharmaceuticals, <i>SK&amp;F 101468-A, SK&amp;F 89124-A, and SK&amp;F 104557-A with Central Adrenergic Receptors</i> , July 1988
	DTX 182				GSK-REQ003824-48, SK&F Report No. PW011BA, <i>The effect of acute intravenous administration of SK&amp;F 101468-A (50 or 500 ug/kg) on respiratory function in anaesthetized cats</i> , March 1987
	DTX 183				GSK-REQ003920-34, Eden, R.J. and D. Owen, SK&F Report No. PW007BA, <i>The dose-related effects on blood pressure and heart rate of the intravenous infusion of SK&amp;F 101468-A to anaesthetized spontaneously hypertensive rats</i> , February 1987
	DTX 185				GSK-REQ004575-80, DeMarinis, R.M. memo to Dr. Wilson, Dr. Ross, Mr. Franz, Mr. Gallagher, Dr. Lafferty, Mr. Shah, Mr. Venslavsky, Ms. Lavanchy, Dr. Wise, Mr. Webster, Dr. Stringer, RE: <i>Summary of Chemistry Discussion Session February 3, 1983</i> , February 16, 1983
	DTX 186				GSK-REQ004581-82, Ross, Gallagher, Weinstock memo to Perchonock re <i>Preparation of Isatin, Oxindole Intermediates Related to SK&amp;F 89124 and SK&amp;F 101468</i> , November 15, 1982
	DTX 187				GSK-REQ004698-4713, DeMarinis R.M., memo to Wilson re Research Chemistry Semiannual Status Report Summary Antianginal/Antihypertension Program November 1, 1981 - April 31, 1982, April 31, 1982
	DTX 188				GSK-REQ004723-34, Gallagher, G., memo to Wilson re <i>Cardiovascular Research Chemistry Report Project from November 1, 1981 to April 30, 1982</i>
	DTX 189				GSK-REQ004832-4869, Ross, Gallagher, DeMarinis memo to Mastrocola re <i>Synthetic Experience Related to SK&amp;F 89124, SK&amp;F 101468, and SK&amp;F 85738</i> , December 27, 1983

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 190				GSK-REQ007128-37, Distribution List - Minutes SK&F 101468 Project Team Meeting, January 20, 1988
	DTX 191				GSK-REQ007215-22, WELWYN Distribution List - Minutes SK&F 101468 Project Team Meeting December 9, 1988
	DTX 192				GSK-REQ007337-7499, Proceedings of R&D Program Project Review - <i>Alpha-Receptor Program Review</i> , November 8, 1984
	DTX 193				GSK-REQ007948-49, Ross, DeMarinis, Gallagher memo to Mastrocola re <i>Conversion of SK&amp;F 89124 to SK&amp;F 101468</i> , January 26, 1984
	DTX 194				GSK-REQ007950-59, Ross to Mastracola re Alternate Synthetic Routes to SK&F 1/26/84
	DTX 195				GSK-REQ008151-55, Welwyn Project Operating Committee, January 1988
	DTX 196				GSK-REQ008158-69, Welwyn Project Operating Committee, Minutes of the Meeting held in Frythe House Conference Room on Wednesday, March 16, 1988
	DTX 197				GSK-REQ008258-61, Lewis memo to Project Leaders re <i>Philadelphia Project Operating Committee Minutes</i> , June 1, 1987
	DTX 198				GSK-REQ008273-87, Distribution List for Project Management Committee, August 6, 1987
	DTX 199				GSK-REQ008361-65, Gill, C. and Philadelphia Project Operating Committee memo re <i>R&amp;D Project Operating Committee Meeting Minutes</i> , October 28, 1985
	DTX 200				GSK-REQ013518-36, Eden, R., A. Wright, and M. Clarke, <i>The Effect of SK&amp;F 101468-A, on the Central Nervous System</i> , February 1987
	DTX 201				GSK-REQ013679-860, <i>Peripheral Dopamine Receptors</i>
	DTX 202				GSK-REQ014418-14429, <i>Draft Minutes of the SK&amp;F 101468-A Project Team Meeting</i> , April 18, 1986.
	DTX 203				GSK-REQ014660-14661, Smith, Kline, and French Laboratories Ltd., <i>Request for Grant of a United Kingdom Patent, No. 8712073</i> , May 21, 1987.



Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 204				GSK-REQ015678-15681, D. Shah and R. DeMarinis memo to Antianginal/Antihypertensive Team re <i>Summary of Antianginal/Antihypertension Research Program Group Meeting - April 13, 1982, April 20 1982.</i>
	DTX 205				GSK-REQ017737-017924, SK&F 101468 <i>Development Plan</i> , July 1985.
	DTX 206				GSK-REQ017977-17981, <i>Minutes of the SK&amp;F 101468 WWCSC Meeting</i> , February 3, 1988.
	DTX 207				GSK-REQ018110-018118, <i>Distribution List for Welwyn Project Operating Committee</i> , September 23, 1987.
	DTX 208				GSK-REQ018186, <i>Acknowledgement and General Assignment of David Andrew Owen</i> , February 16, 1988.
	DTX 209				GSK-REQ018276-18288, Smith, Kline, and French Laboratories Ltd., <i>Request for Grant of a United Kingdom Patent, No. 8712073</i> , May 21, 1987.
	DTX 210				GSK-REQ018291-18294, Smith, Kline, and French Laboratories Ltd., <i>Request for Grant of a European Patent, No. 88304555.1</i> , April 17, 1990.
	DTX 211				GSK-REQ018296-18297, <i>Supplement to European Patent Application 88 304 555.1.</i>
	DTX 212				GSK-REQ023809-23822, Roesler, Judith et al, <i>Effects of Intravenous or Oral Administration of SK&amp;F 101468-A on Arterial Blood Pressure and Heart Rate in the Rat</i> , Internal SK&F Document, January 14, 1983.
	DTX 213				GSK-REQ024772-024774, Wilson, J. memo to A. Blumberg et al re: <i>SK&amp;F 89124 - Implications, Objectives, and Future Plans</i> , February 19 1982.
	DTX 214				GSK-REQ094553-94558, Nomoto, M. et al, <i>The Dopamine D2 Agonist LY 141865, But Not the D1 Agonist SKF 38393, Reverses Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in the Common Marmoset</i> , Neuroscience Letters 57, 37-41, 1985.

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 215				GSK-BAR000116-000121, Neumeyer at al., Journal of Medicinal Chemistry 1974, 17, 1090-1095, Aporphines. 11. Synthesis and Dopaminergic Activity of Monohydroxyaporphines. Total Synthesis of (+)-11-Hydroxyaporphine, (+)-11-Hydroxynoraporphine, and (+)-11-Hydroxy-N-n-propylaporphine"
	DTX 216				GSK-BAR000122-000125, Cannon, Lee, Ihan, Koons & Long, 6-Hydroxy-4-[2(di-n-propylamino)ethyl]indole: Synthesis and Dopaminergic Action, Journal of Medicinal Chemistry 1984, 27, 386-389
	DTX 217				GSK-JEN 001034-1047, Schmidt, M., Pharmacological Characterization of the Dopamine Renal Vascular Receptor. In pharmacology and functional Regulation of Dopaminergic Neurons, 1988
	DTX 218				TEV-RQEXP000356-000357, Neumeyer, John L. Staff Biography <a href="http://www.mclean.harvard.edu/about/bios/detail.php">http://www.mclean.harvard.edu/about/bios/detail.php</a> McLean Hospital: a Harvard Medical School Affiliate
	DTX 219				TEV-RQEXP000358-000469, Cannon, Joseph G., Dopamine Agonists: Structure-activity relationships. The University of Iowa, Iowa City, Iowa
	DTX 220				GSK-SUD000065-86, Mirapex Tablets - Information Booklet
	DTX 221				GSK-SUD000126-162, Requip Tablets- Prescribing Information
	DTX 222				TEV-RQEXP000320-324, Grosset, Katherin, Needleman, Fiona, et al. Switching From Ergot to Nonergot Dopamine Agonists in Parkinson's Disease: A Clinical Series and Five-Drug Dose Conversion Table. Clinical/Scientific Notes Vol.19, No. 11, 2004 pp1370-1374
	DTX 223				TEV-RQEXP000325-329, Weintraub, Daniel, et al. Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease. Arch Neurol. 2006;63:969-973
	DTX 224				TEV-RQEXP000330-334, Voon, V., Hassan, K., Zurokowski, S, et al., Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006;66:1750-1752
	DTX 225				TEV-RQEXP000335-342, Avorn, Jerry, et al. Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease. Arch Neurol 2005;62:1242-1248

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 226				TEV-RQEXP000343-348, Razmy, Ajmal. <i>Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated with Older (Ergot) vs Newer (Nonergot) Dopamine Agonists</i> . Arch Neurol. 2004;61:97-102
	DTX 227				TEV-RQEXP000349-355, Tan, Eng-King; Jankovic, Joseph. <i>Choosing Dopamine Agonists in Parkinson's Disease</i> . Clinical Neuropharmacology Vol. 24, No. 5, pp. 247-253, 2001
	DTX 228				GSK-JEN000072-79, Cannon, J., <i>Future Directions in Dopaminergic Nervous System and Dopaminergic Agonists</i> , J. Med. Chem. Vol. 24, No. 10, Oct. 1981
	DTX 229				GSK-JEN000127-133, Carlsson, A., <i>Dopamine Receptor Agonists: Intrinsic Activity vs. State of Receptor</i> , J. Neural Transmission 57, 309-315, 1983
	DTX 230				GSK-JEN000143-147, Carlsson, A., <i>The intrinsic Activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats</i> . Eur.J Pharmacol. 142 (1):39-43, 1987
	DTX 231				GSK-JEN000606-615, Goldberg, L., <i>Dopamine receptors and hypertension. Physiologic and pharmacologic implications</i> , Am.J.Med., 1984
	DTX 232				GSK-JEN000798-801, Keibadian, J., <i>Multiple Receptors for Dopamine</i> , Nature, 1979
	DTX 233				GSK-JEN000802-807, Keibadian, J., <i>Pharmacological and biochemical evidence for the existence of two categories of dopamine receptor</i> , Can.J.Neurol.Sci. 11, 1984
	DTX 234				TEV-RQEXP000470-1, <i>The Process of Drug Development: Drug Development: The Short Story. 7. The Cost of Drug Development.</i> , <a href="http://www.netsci.org/scgi-bin/Courseware/projector.pl?Course_num=course1&amp;Filename=slide07.html">http://www.netsci.org/scgi-bin/Courseware/projector.pl?Course_num=course1&amp;Filename=slide07.html</a>
	DTX 235				TEV-RQEXP000472-506, <i>The Price of Innovation - New Estimates of Drug Development Costs</i> , <a href="http://www.cptech.org/ip/health/econ/dimasi2003.pdf">http://www.cptech.org/ip/health/econ/dimasi2003.pdf</a>
	DTX 236				TEV-RQEXP000507-12, <i>New Estimates of Drug Development Costs</i> , <a href="http://www.cptech.org/ip/health/econ/frank2003.pdf">http://www.cptech.org/ip/health/econ/frank2003.pdf</a>

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 237				TEV-RQEXP 000513-5, <i>Tufts Center for the Study of Drug Development</i> , <a href="http://csdd.tufts.edu/NewsEvents/RecentNews.asp?new_sid=6">http://csdd.tufts.edu/NewsEvents/RecentNews.asp?new_sid=6</a>
	DTX 238				TEV-RQEXP 000516-7, C&EN - <i>Today's Headlines - Drug Development Costs about \$1.7 Billion</i> , <a href="http://pubs.acs.org/cen/topstory/8150/8150notw5.html">http://pubs.acs.org/cen/topstory/8150/8150notw5.html</a>
	DTX 239				TEV-RQEXP 000518-20, <i>The Real Cost of Drug Development</i> , <a href="http://www.touchbriefings.com/pdf/1842/Chris_Adams.pdf">http://www.touchbriefings.com/pdf/1842/Chris_Adams.pdf</a>
	DTX 240				TEV-RQEXP 000521-4, <i>Parkinson's Disease Treatments</i> , <a href="http://hcd2.bupa.co.uk/fact_sheets/html/Parkinsons_disease.html">http://hcd2.bupa.co.uk/fact_sheets/html/Parkinsons_disease.html</a>
	DTX 241				TEV-RQEXP 000525-6, <i>Parkinson's Disease - Treatment Options - Conditions and Treatments - Drug Digest</i> , <a href="http://www.drugdigest.org/DD/HC/Treatment/0,4047,550186,00.html">http://www.drugdigest.org/DD/HC/Treatment/0,4047,550186,00.html</a>
	DTX 242				TEV-RQEXP 000527, <i>The History of Drugs for the Treatment of Parkinson's Disease</i> , <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1491242&amp;dopt=Abstract">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1491242&amp;dopt=Abstract</a>
	DTX 243				TEV-RQEXP000528, Verispan Data (CD)
	DTX 243.1				Verispan's Physician Drug & Diagnosis Audit
	DTX 243.2				Verispan's Direct-to-Consumer Advertising Audit
	DTX 244				GSK-REQ021142-21152, Market 3/1 PLAN 2001-2003; <i>Market: Parkinson's Disease Requip for use by Pharmaceuticals Europe and North America</i>
	DTX 245				GSK-REQ025445-25499, Requip NH Directors Meeting October 2002
	DTX 246				GSK-REQ025631-25672, Requip Clinical Specialist Brand Strategy and Q&A. Kevin Reeves-Brand Director
	DTX 247				GSK-REQ025674-25691, Reeves, K., Brand Director, <i>Realizing the Power: Brand Overview &amp; Tactical Plan for Requip</i> .

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 248				GSK-REQ025722-25738, Richardson, L.M., Senior Product Manager, <i>Realizing the Power: Requip RLS 2003 Plan Review</i> .
	DTX 249				GSK-REQ025775-25787, Requip PD 2002-2003 Planning
	DTX 250				GSK-REQ055075-55136, May 14 <sup>th</sup> , 2001 Powerpoint: Requip 2001 Situation Analysis - Data Pack
	DTX 251				GSK-REQ055412-55462, 8/28/2002 Requip 2002 Strategic Plan Review
	DTX 252				GSK-REQ055481-55523, 4/19/2002 Requip 2002 Situation Analysis
	DTX 253				GSK-REQ057660-57712, 6/11/2004 Requip 2004 Situation Analysis
	DTX 254				GSK-REQ063872-63917, 4/19/2002 Requip 2002 Situation Analysis
	DTX 255				GSK-REQ063665-63666, 6/7/2001 The Strategic Brand Plan: Situation Analysis
	DTX 256				GSK-REQ 021019-21075, Requip 2000 Situation Analysis
	DTX 257				GSK-REQ 028534-28547, <i>Requip, Ropinerole HCl for Restless Leg Syndrome</i> Powerpoint Presentation
	DTX 258				GSK-REQ 055068-55074, Requip 2001 Situation Analysis
	DTX 259				GSK-REQ 055527-55533, Requip 2001 Situation Analysis
	DTX 260				GSK-REQ 056762-56763, Requip Market Expansion as a result of treating the previously untreated PD patients earlier in disease state- Data Table Prepared by Scott Levin
	DTX 261				GSK-REQ 057713-57789, Requip 2004 Situation Analysis: Restless Leg Syndrome dated June 11, 2003
	DTX 262				GSK-REQ 057820-57877, Requip 2006 Situation Analysis Data Pack
	DTX 263				GSK-REQ 057878-57957, REQUIP IR and REQUIP 24-Hour 2006 Strategic Plan, July 29 PM DRAFT
	DTX 264				GSK-REQ 057996-58048, Requip 2006 Situation Analysis: Restless Leg Syndrome



Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 265				GSK-REQ 060654-60700, Requip Pricing Strategy dated October 2003
	DTX 266				GSK-REQ 060774-60776, Verispan, PDDA (MAT Ending August 2003)
	DTX 267				GSK-REQ060781-061031, <i>RLS Market Dynamics Study Baseline (Pre-Launch)</i> Final Report. January 2004
	DTX 268				GSK-REQ061032-061218, <i>RLS Market Dynamics Study Baseline (Pre-Launch)</i> Final Report. May 11, 2004
	DTX 269				GSK-REQ061219-061640, Princeton Brand Economics; <i>Detailed Findings from Requip Targeting Check Study</i> by Barry L. Tannenholz. December 15, 2003
	DTX 270				GSK-REQ061648-061659, Requip Data of Prevalence of RLS and Revenue
	DTX 271				GSK-REQ061672-061683, Requip Data of Prevalence of RLS and Revenue
	DTX 272				GSK-REQ061696-061707, Requip Data of Prevalence of RLS and Revenue
	DTX 273				GSK-REQ061708-061723, Requip Data of Prevalence of RLS and Revenue
	DTX 274				GSK-REQ061736-061747, Requip Data of Prevalence of RLS and Revenue
	DTX 275				GSK-REQ061748-061763, Requip Data of Prevalence of RLS and Revenue
	DTX 276				GSK-REQ061776-061787, Requip Data of Prevalence of RLS and Revenue
	DTX 277				GSK-REQ061800-061833, <i>Pharmaceutical Business Forecasting Restless Legs Syndrome</i> by The Mattson Jack Group
	DTX 278				GSK-REQ063667-63720, <i>ReQuip 2003 Situation Analysis</i> , June 11, 2003.
	DTX 279				GSK-REQ063721-63725, ReQuip PD Situational Analysis - Executive Summary, 2003
	DTX 280				GSK-REQ063726-63727, <i>The Strategic Brand Plan: Situation Analysis</i>

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 281				GSK-REQ063728-63729, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 282				GSK-REQ063730-63731, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 283				GSK-REQ063758-63764, <i>ReQuip 2001 Situation Analysis</i> , May 14, 2001
	DTX 284				GSK-REQ063784-63843, <i>ReQuip 2003 Situation Analysis Restless Legs Syndrome</i> , June 11, 2003
	DTX 285				GSK-REQ063844-63848, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 286				GSK-REQ063849-63855, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 287				GSK-REQ063856-63861, <i>ReQuip Ropinirole, HCL</i> , Situation Analysis, 2003
	DTX 288				GSK-REQ063862-63867, <i>The Strategic Brand Plan: Key Issues and Brand Strategies</i>
	DTX 289				GSK-REQ063922, <i>Anti-Parkinson's Market Monthly Data Pack</i> , August 2003
	DTX 290				GSK-REQ064062-64063, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 291				GSK-REQ064065-64066, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 292				GSK-REQ064071-64077, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 293				GSK-REQ064078-64085, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 294				GSK-REQ064091-64093, <i>The Strategic Brand Plan: Brand Positioning Statements: RLS</i> , August 7, 2002
	DTX 295				GSK-REQ064094-64095, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 296				GSK-REQ064096-64103, <i>The Strategic Brand Plan: SWOT Analysis: RLS</i> , August 7, 2002
	DTX 297				GSK-REQ064180-64192, <i>Swiftwater Group, Growth Analysis</i>
	DTX 298				GSK-REQ064197-64245, <i>ReQuip 2004 Situation Analysis</i> , June 11, 2004

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 299				GSK-REQ064246-64298, <i>ReQuip 2004 Situation Analysis</i> , June 11, 2004
	DTX 300				GSK-REQ064299-64375, <i>ReQuip 2004 Situation Analysis Restless Legs Syndrome</i> , June 11, 2004
	DTX 301				GSK-REQ064555-64559, <i>The Strategic Brand Plan: SWOT Analysis: RLS</i> , August 7, 2002
	DTX 302				GSK-REQ064599-64623, <i>ReQuip RLS 2004 Non-Financial Brand Plan</i> , September 9, 2003
	DTX 303				GSK-REQ064624-64683, <i>ReQuip PD Strat Plan 2005 Presentation</i> , August 31, 2004
	DTX 304				GSK-REQ064689-64697, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 305				GSK-REQ064698-64706, <i>ReQuip Ropinirole HCL</i> , Situation Analysis, 2003
	DTX 306				GSK-REQ064707-64717, <i>ReQuip Ropinirole HCL</i> , Situational Analysis - Executive Summary, 2003
	DTX 307				GSK-REQ064718-64728, <i>ReQuip Ropinirole HCL</i> , Situational Analysis - Executive Summary, 2003
	DTX 308				GSK-REQ064729-64739, <i>ReQuip Ropinirole HCL</i> , Situational Analysis - Executive Summary, 2003
	DTX 309				GSK-REQ064740-64750, <i>ReQuip Ropinirole HCL</i> , Situational Analysis - Executive Summary, 2003
	DTX 310				GSK-REQ064756-64784, <i>ReQuip PD Strat Plan 2005 Presentation</i> , August 2, 2004
	DTX 311				GSK-REQ094317-94433, Prosecution History for U.S. Patent No. 4,452,808
	DTX 312				GSK-REQ094434-94657, Prosecution History for U.S. Patent No. 4,824,860
	DTX 313				GSK-REQ094658-94863, Prosecution History for U.S. Patent No. 4,314,944
	DTX 314				GSK-REQ023414-23534, <i>July 21, 1983 Antianginal/Antihypertensive Review</i> , July 12, 1983
	DTX 315				GSK-REQ024355-24364, February 11, 1983 Report on the Activities of SK&F 85738-H, SK&F 89124-A and SK&f 101468-A in the Hexobarbital Sleep Time and CMA Tests as Predictors of Potential Sedative Liability



Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 316				<a href="http://www.requip.com/tv_commercial.html">http://www.requip.com/tv_commercial.html</a>
	DTX 317				DX 140, Bartlett, P.A., Notice of Deposition, October 18, 2006
	DTX 318				DX 141, Bartlett, P.A., Curriculum Vitae
	DTX 319				DX 142, DeMarinis, R.M. and G. Gallagher et al., <i>Synthesis and in Vitro Evaluation of 4-(2-Aminoethyl)-2(3H)-indoles and Related Compounds as Peripheral Projunctional Dopamine Receptor Agonists</i> , J. Med. Chem, Vol. 29, 939-947, 1986
	DTX 320				DX 143, DeMarinis, R.M., Compound 31
	DTX 321				DX 144, Hieble, J.P. and R.M. DeMarinis memo to Dr. Berkowitz and Dr. Hecht re <i>Recommendation of SK&amp;F 85738, 89124 and 101468 for Development Project Status</i> , May 25, 1984
	DTX 322				DX 145, Cannon, J.G., Rule 26(a)(2) Expert Report, July 10, 2006
	DTX 323				DX 146, Long, J.P., Rule 26(a)(2) Expert Report, July 10, 2006
	DTX 324				DX 147, Bartlett, P.A., Expert Report, September 22, 2006
	DTX 325				DX 148, Cannon, J.G., <i>Preparation and Biological Actions of Some Symmetrically N,N-Disubstituted Dopamines</i> , J. Med. Chem. Vol. 21 No. 3, 1978
	DTX 326				DX 149, Sumners, C. et al., <i>Neurochemical and Behavioural Profiles of Five Dopamine Analogues</i> , Arch. Pharmacol. 316:304-310, November 4, 1981
	DTX 327				DX 150, Jenner, P.G., Rule 26(a)(2) Expert Report
	DTX 328				DX 151, Cannon, J.G., <i>Proposed Dopaminergic Pharmacophore of Lergotile, Pergolide, and Related Ergot Alkaloid Derivatives</i> , Communications to the Editor, J. Med. Chem. 24, 238-240, 1981
	DTX 329				DX 152, Cannon, J.G., <i>Future Directions in Dopaminergic Nervous System and Dopaminergic Agonists</i> , J. Med. Chem Vol. 24 No. 10, 1981
	DTX 330				DX 153, Rienzi, M., letter to C. Brahma re documents considered by GSK experts, October 17, 2006.
	DTX 331				DX 154, Sudarsky, L., Revised Notice of Deposition, October 23, 2006

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 332				DX 155, Sudarsky, L., Curriculum Vitae
	DTX 333				DX 156, Sudarsky, L., Rule 26(a)(2) Expert Report
	DTX 334				DX 157, Vellturo, C. Expert Report
	DTX 335				DX 158, Requip Situational Analysis - Executive Report
	DTX 336				DX 159, Requip 2001 Tactical Plan
	DTX 337				DX 160, Website printout, <a href="http://www.requip.com/index.html">http://www.requip.com/index.html</a>
	DTX 338				DX 161, Requip - What Are Some Common Questions?
	DTX 339				DX 162, Requip - RLS Marketing Update
	DTX 340				DX 163, Jeanne Whalen, <i>How Glaxo Marketed a Malady to Sell a Drug</i> , The Wall Street Journal, Oct. 26, 2006
	DTX 341				GSK-JEN000087-99, Letter from M. Rienzi to C. Brahma, Teva Motion in limine No. 4 Exhibit I, June 27, 2006
	DTX 342				Cannon, J.G., J.P. Long, and B.J. Demopoulos, <i>Indole-derived Fragments of Ergot Alkaloids as Dopamine Congeners</i> , Iowa. Pharmac. Acad., July 1981
	DTX 343				Boghigian Report Exhibit D
	DTX 344				Boghigian Report Exhibit D-1
	DTX 345				Boghigian Report Exhibit D-2
	DTX 346				Boghigian Report Exhibit E
	DTX 347				Boghigian Report Exhibit E-1
	DTX 348				Boghigian Report Exhibit F
	DTX 349				Boghigian Report Exhibit G
	DTX 350				Boghigian Report Exhibit G-1
	DTX 351				Boghigian Report Exhibit H
	DTX 352				Boghigian Report Exhibit H-1
	DTX 353				Boghigian Report Exhibit I

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 355				Curriculum Vitae, Boghigian, H.C.
	DTX 356				Curriculum Vitae, Cannon, J.G.
	DTX 357				Curriculum Vitae, Long, J.P.
	DTX 358				Curriculum Vitae, Tarsy, D.
	DTX 359				Rule 26(a)(2) Expert Report, Tarsy, D., July 10, 2006
	DTX 361				Rule 26(a)(2) Corrected Rebuttal Expert Report, Boghigian, H.C., October 18, 2006
	DTX 362				Rule 26(a)(2) Rebuttal Expert Report, Cannon, J.G., October 6, 2006
	DTX 363				Rule 26(a)(2) Rebuttal Expert Report, Long, J.P., October 6, 2006
	DTX 364				Rule 26(a)(2) Rebuttal Expert Report, Tarsy, D., October 5, 2006
	DTX 365				Cannon, J.G., Rule 26(a)(2) Expert Report, July 10, 2006
	DTX 366				Exhibit C, Rule 26(a)(2) Rebuttal Expert Report, Boghigian, H., November 11, 2006
	DTX 367				Exhibit B, Rule 26(a)(2) Rebuttal Expert Report, Cannon, J., October 6, 2006
	DTX 368				Exhibit B, Rule 26(a)(2) Rebuttal Expert Report, Long, J., October 6, 2006
	DTX 370				Exhibit A, Rule 26(a)(2) Rebuttal Expert Report, Tarsy, D., October 5, 2006
	DTX 371				DX 166, Chemical Structure
	DTX 372				DX 167, Chemical Structure
	DTX 373				DX 168, Chemical Structure
	DTX 374				DX 169, Arnt, J., <i>Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection of rats</i> , Arch. Of Pharm., 1985
	DTX 375				DX 171, Holden, K., United States Patent 4,206,210, June 3, 1980

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 376				DX 172, Hieble, P. et al., <i>Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benzimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines</i> , J. Med. Chem., 1987
	DTX 377				DX 173, Kaiser, C. and T. Jain, <i>Dopamine Receptors: Functions, Subtypes and Emerging Concepts</i> , Medicinal Research Reviews, Vol. 5, No. 2, 145-229, 1985
	DTX 378				DX 174, Trivastal - Summary of Product Characteristics, servier.com website
	DTX 379				DX 175, Bossier, J.R., <i>Simplified Ergolines as New Dopamine Agonists</i>
	DTX 380				DX 176, Dr. Jenner's 2005 Publications
	DTX 381				DX 177, Dr. Jenner's 2006 Publications
	DTX 382				DX 178, Laduron, P.M. and J. Leysen, <i>Domperidone, A Specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity</i>
	DTX 383				Plaintiff GSK's Third Supplemental Responses to Defendant's First Set of Interrogatories; August 16th, 2006
	DTX 384				Fifth Privilege Log of Plaintiff GSK; August 17th, 2006
	DTX 385				Sixth Privilege Log of Plaintiff GSK, August 18th, 2006
	DTX 386				Certificate of Correction for patent 4,452,808; Gregory Gallagher; June 5th, 1984
	DTX 387				Letter from Wilmer Hale to G. Gallagher; June 5th, 2005
	DTX 388				www.requip.com, Requip Website, December 8th, 2006
	DTX 389				www.mirapex.com, Mirapex Website, December 8, 2006
	DTX 390				Kebabian, J. W. and D. B. Calne, <i>Multiple receptors for dopamine</i> , Nature. 277 (5692): 93-96 (1979).

Teva provides this draft exhibit list pursuant to the parties' agreement to jointly prepare an exhibit list in compliance with the Court's standing order for final pre-trial orders. Teva's draft list provided to plaintiffs is without prejudice to Teva's right to object to the admissibility of any exhibit if offered by plaintiffs, including exhibits appearing on Teva's draft exhibit list. Teva reserves the right to amend this list as circumstances may warrant.

# **EXHIBIT B**

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
PTX 13		JTX 1	Gallagher, G., U.S. Patent 4,452,808, June 5, 1984, with certificate of correction
PTX 14	DTX 311	JTX 2	GSK-REQ094317-94433, Internal Prosecution History for U.S. Patent No. 4,452,808
PTX 15	DTX 64	JTX 3	DX-64, Huffman, W. et al., <i>Communications to the Editor re 4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a Novel Class of Potent Presynaptic Dopamine Receptor Agonists</i> , J. Med. Chem., July 1983
PTX 17	DTX 30	JTX 4	DX-30, G. Gallagher et al: <i>4-[2-(Di-n-propylamine)ethyl]-2(3H) indolone: A Prejunctional Dopamine Receptor Agonist</i> , J. Med. Chem. 28: 1533-1536 1985
PTX 21	DTX 56	JTX 5	DX-56, R. DeMarinis et al, <i>Syntheses and In Vitro Evaluation of 4-(2-aminoethyl)-2-3(H)-Indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists</i> , 1986
PTX 23	DTX 24	JTX 6	DX-24, Wright, A., Laboratory Notebook, July 2, 1986
PTX 26	DTX 35	JTX 7	DX-35, B. Costall and R.J. Naylor: <i>SK&amp;F 101468-A: a centrally acting dopamine agonist having antiparkinson, antidepressant and anxiolytic activity</i> , July 9, 1987
PTX 35	DTX 48	JTX 8	DX-48, Owen et al., U.S. Patent 4,824,860, April 25, 1989
PTX 36	DTX 47	JTX 9	DX-47, Huffman et al., U.S. Patent 4,314,944, February 9, 1982
PTX 37	DTX 312	JTX 10	GSK-REQ094434-94657, Internal Prosecution History for U.S. Patent No. 4,824,860
PTX 40	DTX 38	JTX 11	DX-38, Costall, B. et al., <i>The Effects of chronic administration of SK&amp;F 101468-A in the MPTP-treated common marmoset (Callithrix jacchus)</i> , May 1989
PTX 45	DTX 97	JTX 12	DX-97, Owen, D., Declaration and Power of Attorney, May 19, 1988
PTX 48	DTX 43	JTX 13	DX-43, Profile of Ropinirole and SK&F #89124
PTX 49, 75	DTX 55	JTX 14	DX-55, Chemical Formulas for 88827 and 89124
PTX 74	DTX 33	JTX 15	DX-33, Costall, B., Curriculum Vitae
PTX 76	DTX 20	JTX 16	TEV-RQEXP000587-638, Public Prosecution History for '808 Patent



## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
PTX 77	DTX 19	JTX 17	TEV-RQEXP000529-586, Public Prosecution History for '860 Patent
PTX 96	DTX 160	JTX 18	TEV-RQEXP000047-052, Cannon, J.G., Hsu, F., Long, J.P., Flynn, J.R., Costall, B., and Naylor, R.J., <i>Preparation and Biological Actions of Some Symmetrically N, N-Disubstituted Dopamines</i> , J. Med. Chem., 1978, Vol. 21, No. 3: 248-253.
PTX 116	DTX 62	JTX 19	DX-62, J. Cannon et al: <i>Proposed Dopaminergic Pharmacophore of Lergotile, Pergolide, and Related Ergot Alkaloid Derivatives</i> J. Med. Chem. 24:238-240 (1981)
PTX 125	DTX 326	JTX 20	DX 149, Sumners, C. et al., <i>Neurochemical and Behavioural Profiles of Five Dopamine Analogues</i> , Arch. Pharmacol. 316:304-310, November 4, 1981
PTX 156	DTX 161; 216	JTX 21	TEV-RQEXP000053-056, Cannon, J.G., Lee, T., Ilhan, M., Koons, J. and Long, J.P., <i>6-Hydroxy-4-[2-(di-n-propylamino)ethyl]indole: Synthesis and Dopaminergic Actions</i> , J. of Medicinal Chemistry, 1984, Vol. 27: 386.
PTX 171	DTX 219	JTX 22	TEV-RQEXP000358-000469, Cannon, Joseph G., <i>Dopamine Agonists: Structure-activity relationships</i> . The University of Iowa, Iowa City, Iowa
PTX 181	DTX 40	JTX 23	GSK-JEN000106-112, Cannon, J., <i>The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids?</i> , The Proceedings of The Iowa Academy of Science 93(4): 169-174, 1986
PTX 291	DTX 162	JTX 24	TEV-RQEXP000057-058, Cannon, J.G., Long, J.P. and Demopoulos, B.J., <i>Indole-Derived Fragments of Ergot Alkaloids as Dopamine Congeners</i> , 8 <sup>th</sup> International Congress of Pharmacology, Satellite Symposium.
PTX 353	DTX 221	JTX 25	GSK-SUD000126-162, Requip Tablets- Prescribing Information
PTX 300		JTX 26	Parkinson's Disease Backgrounder: National Institute of Neurological Disorders and Stroke, <a href="http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm">http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm</a>
PTX 341		JTX 27	National Institute of Neurological Disorders and Stroke: Parkinson's Disease: Hope Through Research
PTX 302		JTX 28	The Michael J. Fox Foundation for Parkinson's Research, <a href="http://www.michaeljfox.org/parkinsons/">http://www.michaeljfox.org/parkinsons/</a> .
	DTX 23	JTX 29	DX-23, SK&F Project Meeting Minutes March 13, 1986



## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 25	JTX 30	DX-25, SK&F Project Meeting Minutes February 27, 1987
	DTX 28	JTX 31	DX-28, Draft Project Plan, August 1987
	DTX 29	JTX 32	DX-29, J.P. Hieble and R. DeMarinis memo to Berkowitz, B. and S. Hecht re <i>Recommendation for Development Project Status</i> , May 25, 1984
	DTX 36	JTX 33	DX-36, Costall, B. and R.J. Naylor, <i>Action of SK&amp;F 101468-A in mice with unilateral 6-OHDA lesions of the substantia nigra</i> , September 1987
	DTX 37	JTX 34	DX-37, Costall, B. and R.J. Naylor, <i>Action of SK&amp;F 101468-A in a Model of Parkinson's Disease induced by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the common marmoset</i> , September 1987
	DTX 39	JTX 35	DX-39, Preclinical Profile of SK&F 101468-A (Ropinirole)
	DTX 42	JTX 36	DX-42, Gallagher, G., U.S. Patent 4,452,808, June 5, 1984
	DTX 57	JTX 37	DX-57, J. Walker et al., <i>Substituted Oxindoles: Synthesis and Pharmacology of Some Substituted Oxindoles</i> , J. Med. Chem., May 19, 1970
	DTX 61	JTX 38	DX-61, Nishi, T., Japanese Unexamined Patent Application Publication: <i>Oxyindole derivatives and a method of preparation of the same - S51-36281</i> , March 31, 1976
	DTX 65	JTX 39	Japanese Patent No. 52-118465, October 4, 1977
	DTX 66	JTX 40	Japanese Patent No. 53-18562, February 20, 1978
	DTX 68	JTX 41	DX-68, SK&F Project Meeting Minutes December 4, 1985
PTX 22	DTX 69	JTX 42	DX-69, SK&F Project Meeting Minutes January 9, 1986
PTX 20	DTX 70	JTX 43	DX-70, SK&F Project Meeting Minutes December 9, 1985
	DTX 71	JTX 44	DX-71, Department of Drug Metabolism and Pharmacokinetics: <i>Preliminary Investigation into the C.N.S. Penetration of SK&amp;F 101468 and Related Material in the Conscious Rat</i> , March 1986
	DTX 72	JTX 45	DX-72, SK&F Project Meeting Minutes, February 10, 1986
	DTX 73	JTX 46	DX-73, SK&F Project Meeting Minutes, April 18, 1986
	DTX 74	JTX 47	DX-74, SK&F Project Meeting Minutes, May 29, 1986
	DTX 75	JTX 48	DX-75, SK&F Project Meeting Minutes, September 3, 1986

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 76	JTX 49	DX-76, SK&F Project Meeting Minutes, October 30, 1986
	DTX 77	JTX 50	DX-77, SK&F Project Meeting Minutes, December 11, 1986
	DTX 78	JTX 51	DX-78, SK&F Project Meeting Minutes, February 18, 1987
	DTX 79	JTX 52	DX-79, SK&F Project Meeting Minutes, February 27, 1987
	DTX 80	JTX 53	DX-80, Welwyn Project Operating Committee Meeting Minutes, May 20, 1987
	DTX 84	JTX 54	DX-84, SK&F Project Meeting Minutes, July 1, 1987
	DTX 85	JTX 55	DX-85, Welwyn Project Committee Meeting Minutes, October 7, 1987
PTX 31	DTX 86	JTX 56	DX-86, SK&F Project Review Panel memo to SK&F 101468 Project Team re <i>Critique of SK&amp;F 101468</i> , October 12, 1987
	DTX 87	JTX 57	DX-87, SK&F Project Meeting Minutes November 11, 1987
	DTX 89	JTX 58	DX-89, SK&F Project Meeting Minutes, March 3, 1988
	DTX 90, 105	JTX 59	DX-90, SK&F Project Meeting Minutes May 18, 1988
	DTX 93	JTX 60	DX-93, Costall, B. et al., <i>Pharmacological Evaluation of SK&amp;F 101468-A in MPTP Treated Marmosets</i> , 1990
	DTX 94	JTX 61	DX-94, Hieble, J.P. et al., <i>Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on the Intact Animal</i>
	DTX 96	JTX 62	DX-96, Wixon, H. email to D. Owen re GSK Retention Confirmation
	DTX 98	JTX 63	DX-98, SK&F Project Meeting Minutes May 29, 1986
	DTX 99	JTX 64	DX-99, SK&F Project Meeting Minutes September 28, 1988
	DTX 100	JTX 65	DX-100, SK&F Project Meeting Minutes October 30, 1986
PTX 25	DTX 101	JTX 66	DX-101, SK&F Project Meeting Minutes July 16, 1986
	DTX 102	JTX 67	DX-102, SK&F Project Meeting Minutes September 3, 1986
	DTX 104	JTX 68	DX-104, SK&F Project Meeting Minutes July 1, 1987
	DTX 106	JTX 69	DX-106, GSK Supplemental Responses to Teva's 1 <sup>st</sup> Set of Interrogatories, April 10, 2006

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 107	JTX 70	DX-107, Strategic Brand Plan: (01) Brand Summary
	DTX 108	JTX 71	DX-108, ReQuip 2001 Situational Analysis, May 14, 2001
	DTX 112	JTX 72	DX-112, Strategic Brand Plan Situation Analysis, June 7, 2001
	DTX 113	JTX 73	DX-113, ReQuip Differentiation Strategy Approach Topline Report
PTX 258	DTX 120	JTX 74	DX-120, ReQuip 2001 Tactical Plan Revised, December 21, 2000
PTX 72	DTX 125	JTX 75	DX-125, ReQuip Brand P&L Chart, 1997-2005
	DTX 132	JTX 76	DX-132, Revised Privilege Log of GSK April 18, 2006
	DTX 133	JTX 77	DX-133, Giddings, P.J., letter to European Patent Office, November 25, 1991
	DTX 134	JTX 78	DX-134, European Patent Office letter to P.J. Giddings, July 26, 1991
	DTX 135	JTX 79	DX-135, SK&F Project Meeting Minutes August 8, 1987
	DTX 136	JTX 80	DX-136, Second Privilege Log of GSK May 2, 2006
	DTX 137	JTX 81	DX-137, Third Privilege Log of GSK May 24, 2006
	DTX 138	JTX 82	DX-138, Fourth Privilege Log of GSK May 31, 2006
	DTX 140	JTX 83	Plaintiff GSK's Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, October 3, 2005
	DTX 141	JTX 84	Plaintiff GSK's Supplemental Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, April 10, 2006
	DTX 142	JTX 85	Plaintiff GSK's 2 <sup>nd</sup> Supplemental Responses to Defendant's 1 <sup>st</sup> Set of Interrogatories, June 29, 2006
	DTX 149	JTX 86	GSK-REQ 004723-734, Gallagher, G. memo to J.W. Wilson and S. Ross re <i>Cardiovascular Research Chemistry Report Antianginal/Antihypertension Project November 1, 1981 to April 30, 1982</i>
	DTX 150	JTX 87	GSK-REQ005139-142, Costall, B., Eden R.J., Harvey, C.A., Kelly, M.E. and Owen, D.A.A., <i>SK&amp;F 101468-A, A Possible Drug for Treatment of Parkinson's Disease</i> , Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases; 1990, Vol. 2, ed. by T. Nagatsu et al., Plenum Press, New York.



## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
PTX 427	DTX 158	JTX 88	Cannon, J.G., <i>Dopamine Congeners Derived from the Benzo(f)-quinoline Ring</i> , Adv. in Biosciences, 1979, 20: 87-94
	DTX 163	JTX 89	Costall, B. and Naylor, R.J., <i>Actions of Dopaminergic Agonists on Motor Function</i> , Advances in Neurology, 1975, Vol. 9, ed. By D.B. Calne, T.N. Chase and A. Barbeau, 293
PTX 92	DTX 164	JTX 90	Geissler, H., <i>3-{2-(Dipropylamino)ethyl}phenol : a new and selective dopaminergic agonist</i> , Arch. Pharm. (Weinheim), 1977, Vol. 310:749-756
	DTX 167	JTX 91	Joule, J.A. and Smith, G.F., <i>Heterocyclic Chemistry</i> , 1972, p. 278
	DTX 170	JTX 92	Long, J.P., Gebhart, G.F., Flynn, J.R. and Cannon, J.G., <i>Vascular and Cardiac Actions of N-di-Alkyl Dopamine Analogs</i> , Arch. Int. Pharmacodyn., 1980, Vol 245: 104-117
	DTX 172	JTX 93	TEV-RQEXP000217-220, Steinsland, O. and Hieble, J.P., <i>Dopaminergic Inhibition of Andrenergic Neurotransmission as a Model for Studies on Dopamine Receptor Mechanisms</i> , Science, 1978, Vol. 199:443-445
	DTX 177	JTX 94	Teitel, S. and O'Brien, J.P., <i>Selective Removal of an Aromatic Methylenedioxy Group</i> , J. Org. Chem., 1975, Vol. 41, NO. 9:1657
	DTX 183	JTX 95	GSK-REQ003920-34, Eden, R.J. and D. Owen, SK&F Report No. PW007BA, <i>The dose-related effects on blood pressure and heart rate of the intravenous infusion of SK&amp;K 101468-A to ananesthetised spontaneously hypertensive rats</i> , February 1987
	DTX 190	JTX 96	GSK-REQ007128-37, Distribution List - Minutes SK&F 101468 Project Team Meeting, January 20, 1988
	DTX 191	JTX 97	GSK-REQ007215-22, WELWYN Distribution List - Minutes SK&F 101468 Project Team Meeting December 9, 1988
	DTX 192	JTX 98	GSK-REQ007337-7499, Proceedings of R&D Program Project Review - <i>Alpha-Receptor Program Review</i> , November 8, 1984
PTX 34	DTX 196	JTX 99	GSK-REQ008158-69, Welwyn Project Operating Committee, Minutes of the Meeting held in Frythe House Conference Room on Wednesday, March 16, 1988
	DTX 197	JTX 100	GSK-REQ008258-61, Lewis memo to Project Leaders re <i>Philadelphia Project Operating Committee Minutes</i> , June 1, 1987
	DTX 198	JTX 101	GSK-REQ008273-87, Distribution List for Project Management Committee, August 6, 1987
	DTX 199	JTX 102	GSK-REQ008361-65, Gill, C. and Philadelphia Project Operating Committee memo re <i>R&amp;D Project Operating Committee Meeting</i>

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
			Minutes, October 28, 1985
	DTX 202	JTX 103	GSK-REQ014418-14429, Draft Minutes of the SK&F 101468-A Project Team Meeting, April 18, 1986.
	DTX 204	JTX 104	GSK-REQ015678-15681, D. Shah and R. DeMarinis memo to Antianginal/Antihypertensive Team re Summary of Antianginal/Antihypertension Research Program Group Meeting - April 13, 1982, April 20 1982
	DTX 206	JTX 105	GSK-REQ017977-17981, Minutes of the SK&F 101468 WWCS Meeting, February 3, 1988
	DTX 207	JTX 106	GSK-REQ018110-018118, Distribution List for Welwyn Project Operating Committee, September 23, 1987
PTX 146	DTX 229	JTX 107	GSK-JEN000127-133, Carlsson, A., Dopamine Receptor Agonists: Intrinsic Activity vs. State of Receptor, J. Neural Transmission 57, 309-315, 1983
	DTX 240	JTX 108	TEV-RQEXP 000521-4, Parkinson's Disease Treatments, <a href="http://hcd2.bupa.co.uk/fact_sheets/html/Parkinsons_disease.html">http://hcd2.bupa.co.uk/fact_sheets/html/Parkinsons_disease.html</a>
	DTX 241	JTX 109	TEV-RQEXP 000525-6, Parkinson's Disease - Treatment Options - Conditions and Treatments - Drug Digest, <a href="http://www.drugdigest.org/DD/HC/Treatment/0,4047,550186,00.html">http://www.drugdigest.org/DD/HC/Treatment/0,4047,550186,00.html</a>
	DTX 242	JTX 110	TEV-RQEXP 000527, The History of Drugs for the Treatment of Parkinson's Disease, <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1491242&amp;dopt=Abstract">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1491242&amp;dopt=Abstract</a>
	DTX 243	JTX 111	TEV-RQEXP000528, Verispan Data (CD)
	DTX 243.1	JTX 112	Verispan's Physician Drug & Diagnosis Audit
	DTX 243.2	JTX 113	Verispan's Direct-to-Consumer Advertising Audit
	DTX 244	JTX 114	GSK-REQ021142-21152, Market 3/1 PLAN 2001-2003; Market: Parkinson's Disease Requip for use by Pharmaceuticals Europe and North America
	DTX 245	JTX 115	GSK-REQ025445-25499, Requip NH Directors Meeting October 2002
PTX 375	DTX 246	JTX 116	GSK-REQ025631-25672, Requip Clinical Specialist Brand Strategy and Q&A. Kevin Reeves-Brand Director
PTX 376	DTX 247	JTX 117	GSK-REQ025674-25691, Reeves, K., Brand Director, Realizing the Power: Brand Overview & Tactical Plan for Requip.

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 248	JTX 118	GSK-REQ025722-25738, Richardson, L.M., Senior Product Manager, <i>Realizing the Power: Requip RLS 2003 Plan Review</i> .
PTX 378	DTX 249	JTX 119	GSK-REQ025775-25787, Requip PD 2002-2003 Planning
	DTX 250	JTX 120	GSK-REQ055075-55136, May 14 <sup>th</sup> , 2001 Powerpoint: Requip 2001 Situation Analysis - Data Pack
	DTX 251	JTX 121	GSK-REQ055412-55462, 8/28/2002 Requip 2002 Strategic Plan Review
	DTX 252	JTX 122	GSK-REQ055481-55523, 4/19/2002 Requip 2002 Situation Analysis
	DTX 253	JTX 123	GSK-REQ057660-57712, 6/11/2004 Requip 2004 Situation Analysis
	DTX 255	JTX 124	GSK-REQ063665-63666, 6/7/2001 The Strategic Brand Plan: Situation Analysis
	DTX 256	JTX 125	GSK-REQ 021019-21075, Requip 2000 Situation Analysis
	DTX 257	JTX 126	GSK-REQ 028534-28547, <i>Requip, Ropinerole HCl for Restless Leg Syndrome</i> Powerpoint Presentation
	DTX 258	JTX 127	GSK-REQ 055068-55074, Requip 2001 Situation Analysis
	DTX 260	JTX 128	GSK-REQ 056762-56763, Requip Market Expansion as a result of treating the previously untreated PD patients earlier in disease state- Data Table Prepared by Scott Levin
	DTX 262	JTX 129	GSK-REQ 057820-57877, Requip 2006 Situation Analysis Data Pack
	DTX 267	JTX 130	GSK-REQ060781-061031, <i>RLS Market Dynamics Study Baseline (Pre-Launch)</i> Final Report. January 2004
	DTX 269	JTX 131	GSK-REQ061219-061640, Princeton Brand Economics; <i>Detailed Findings from Requip Targeting Check Study</i> by Barry L. Tannenholz. December 15, 2003
	DTX 277	JTX 132	GSK-REQ061800-061833, <i>Pharmaceutical Business Forecasting Restless Legs Syndrome</i> by The Mattson Jack Group
	DTX 290	JTX 133	GSK-REQ064062-64063, <i>The Strategic Brand Plan: Situation Analysis</i>
	DTX 297	JTX 134	GSK-REQ064180-64192, Swiftwater Group, Growth Analysis



## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 303	JTX 135	GSK-REQ064624-64683, <i>ReQuip PD Strat Plan 2005 Presentation</i> , August 31, 2004
	DTX 316	JTX 136	<a href="http://www.requip.com/tv_commercial.html">http://www.requip.com/tv_commercial.html</a>
	DTX 318	JTX 137	DX 141, Bartlett, P.A., Curriculum Vitae
	DTX 321	JTX 138	DX 144, Hieble, J.P. and R.M. DeMarinis memo to Dr. Berkowitz and Dr. Hecht re <i>Recommendation of SK&amp;F 85738, 89124 and 101468 for Development Project Status</i> , May 25, 1984
	DTX 332	JTX 139	DX 155, Sudarsky, L., Curriculum Vitae
	DTX 341	JTX 140	GSK-JEN000087-99, Letter from M. Rienzi to C. Brahma, Teva Motion in limine No. 4 Exhibit I, June 27, 2006
	DTX 343	JTX 141	Boghigian Report Exhibit D
	DTX 344	JTX 142	Boghigian Report Exhibit D-1
	DTX 345	JTX 143	Boghigian Report Exhibit D-2
	DTX 346	JTX 144	Boghigian Report Exhibit E
	DTX 347	JTX 145	Boghigian Report Exhibit E-1
	DTX 348	JTX 146	Boghigian Report Exhibit F
	DTX 349	JTX 147	Boghigian Report Exhibit G
	DTX 350	JTX 148	Boghigian Report Exhibit G-1
	DTX 351	JTX 149	Boghigian Report Exhibit H
	DTX 352	JTX 150	Boghigian Report Exhibit H-1
	DTX 353	JTX 151	Boghigian Report Exhibit I
	DTX 355	JTX 152	Curriculum Vitae, Boghigian, H.C.
	DTX 356	JTX 153	Curriculum Vitae, Cannon, J.G.
	DTX 357	JTX 154	Curriculum Vitae, Long, J.P.
	DTX 358	JTX 155	Curriculum Vitae, Tarsy, D.
	DTX 371	JTX 156	DX 166, Chemical Structure
	DTX 372	JTX 157	DX 167, Chemical Structure

## Teva's Proposed Joint Exhibit List (12/13/2006)

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
	DTX 373	JTX 158	DX 168, Chemical Structure
	DTX 374	JTX 159	DX 169, Arnt, J., <i>Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection of rats</i> , Arch. Of Pharm., 1985
	DTX 375	JTX 160	DX 171, Holden, K., United States Patent 4,206,210, June 3, 1980
	DTX 376	JTX 161	DX 172, Hieble, P. et al., <i>Synthesis and Evaluation of Non-Catechol D-1 and D-2 Dopamine Receptor Agonists: Benimidazol-2-one, Benzoxazol-2-one, and the Highly Potent Benzothiazol-2-one 7-Ethylamines</i> , J. Med. Chem., 1987
PTX 292	DTX 377	JTX 162	DX 173, Kaiser, C. and T. Jain, <i>Dopamine Receptors: Functions, Subtypes and Emerging Concepts</i> , Medicinal Research Reviews, Vol. 5, No. 2, 145-229, 1985
	DTX 379	JTX 163	DX-175, Boissier, J.R. et al., <i>Simplified Ergolines as New Dopamine Agonists</i> , Acta Pharmaceutica Suecica, Supp. 2 (1983), pp. 120-131
	DTX 383	JTX 164	Plaintiff GSK's Third Supplemental Responses to Defendant's First Set of Interrogatories; August 16th, 2006
	DTX 384	JTX 165	Fifth Privilege Log of Plaintiff GSK; August 17th, 2006
	DTX 385	JTX 166	Sixth Privilege Log of Plaintiff GSK, August 18th, 2006
	DTX 386	JTX 167	Certificate of Correction for patent 4,452,808; Gregory Gallagher; June 5th, 1984
	DTX 387	JTX 168	Letter from Wilmer Hale to G. Gallager; June 5th, 2005
	DTX 388	JTX 169	www.requip.com, Requip Webiste, December 8th, 2006
	DTX 389	JTX 170	www.mirapex.com, Mirapex Website, December 8, 2006
PTX 105	DTX 390	JTX 171	Kebabian, J. W. and D. B. Calne, <i>Multiple receptors for dopamine</i> , Nature. 277 (5692): 93-96 (1979).
PTX 13		JTX 172	Gallagher, G., U.S. Patent 4,452,808, June 5, 1984, with certificate of correction
PTX 413		JTX 173	REQUIP Data Table of Contents
PTX 431		JTX 174	D. Tarsy, <i>Initial Treatment of Parkinson's Disease</i> , Current Treatment Options in Neurology 2006, 8:224-235
PTX 435		JTX 175	Curriculum Vitae of Peter G. Jenner



**Teva's Proposed Joint Exhibit List (12/13/2006)**

Pl.'s Trial Exhibit No.	Def.'s Trial Exhibit No.	Proposed Joint Exhibit	Description
PTX 437		JTX 176	Curriculum Vitae of Christopher A. Velturo